Psoriasis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
{{Psoriasis}} | {{Psoriasis}} | ||
{{CMG}} | {{CMG}}; {{AE}}{{HK}} | ||
==Overview== | ==Overview== | ||
Revision as of 00:46, 21 June 2017
|
Psoriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psoriasis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Psoriasis epidemiology and demographics |
|
Risk calculators and risk factors for Psoriasis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
The prevalence of psoriasis is estimated to be 500 per 100,000 cases to 4600 per 100,000 cases annually. . Psoriasis usually affects individuals of the caucasian race. Psoriasis tends to affect Northern European and South East Asian countries.
Epidemiology and Demographics
Prevalence[1]
- Worldwide, the prevalence of psoriasis ranges from a low of 500 per 100,000 persons to a high of 4600 per 100,000 persons.
- The prevalence of psoriasis in the United States is 2000 per 100,000 persons.
Incidence[2]
- Worldwide, the incidence of psoriasis ranges from a low of 78.9 per 100,000 persons (United States) to 230 per 100,000 persons (Italy).
Age
- The mean age for development of psoriasis can be divided into two peaks with the mean of first peak between 15 years to 25 years of age and mean of second peak occuring at 55 years to 60 years of age.[3]
Ethnicity
- Psoriasis tends to affect Caucasians more than other races with a prevalence of 2500 per 100,000 Caucasian persons in the United states which is higher than other ethnic populations in the country.[4]
Gender
- There is no gender predilection for psoriasis, although women are more severely affected once they develop the disease.[5]
Developed Countries
- Psoriasis tends to affect Northern European and South East Asian countries.[6]
References
- ↑ Langley RG, Krueger GG, Griffiths CE (2005). "Psoriasis: epidemiology, clinical features, and quality of life". Ann. Rheum. Dis. 64 Suppl 2: ii18–23, discussion ii24–5. doi:10.1136/ard.2004.033217. PMC 1766861. PMID 15708928.
- ↑ Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). "Global epidemiology of psoriasis: a systematic review of incidence and prevalence". J. Invest. Dermatol. 133 (2): 377–85. doi:10.1038/jid.2012.339. PMID 23014338.
- ↑ "Psoriasis: epidemiology, clinical features, and quality of life | Annals of the Rheumatic Diseases".
- ↑ Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004). "Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction". J. Investig. Dermatol. Symp. Proc. 9 (2): 136–9. doi:10.1046/j.1087-0024.2003.09102.x. PMID 15083780.
- ↑ "Psoriasis - ScienceDirect".
- ↑ Danielsen K, Olsen AO, Wilsgaard T, Furberg AS (2013). "Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort". Br. J. Dermatol. 168 (6): 1303–10. doi:10.1111/bjd.12230. PMID 23374051.